$NKTR News AstraZeneca's NDA for Naloxegol accepted 3:35

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2013 at 12:44 PM

$NKTR News

AstraZeneca's NDA for Naloxegol accepted 3:35 a.m. Nov. 19, 2013 - MarketWatch.com
Nektar Therapeutics shares soar on earnings, new drug prospects 12:31 p.m. Nov. 8, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 5:21 p.m. Sept. 26, 2013 - Russ Britt
Nike shares swoosh higher after earnings 4:53 p.m. Sept. 26, 2013 - Wallace Witkowski
Nektar shares drop 25% after study misses endpoint 3:45 p.m. Sept. 26, 2013 - Wallace Witkowski
FDA grants fast-track status for Nektar drug 10:43 a.m. Nov. 7, 2012 - MarketWatch.com
S&P 500 clears trendline resistance 10:01 a.m. July 30, 2012 - Michael Ashbaugh
Charting the latest tape bomb 10:02 a.m. July 23, 2012 - Michael Ashbaugh
Wednesday’s biggest gaining & declining stocks 5:04 p.m. Feb. 29, 2012 - Kate Gibson
Nektar sells royalties for two drugs 11:31 a.m. Feb. 29, 2012 - MarketWatch.com
S&P 500 vacillates at the March peak 9:47 a.m. April 4, 2011 - Michael Ashbaugh
Wednesday’s biggest gaining and declining stocks 4:24 p.m. Jan. 19, 2011 - Kate Gibson
Monday’s biggest gaining and declining stocks 4:24 p.m. Dec. 13, 2010 - Kate Gibson
Drug indexes hug the flat line 10:57 a.m. Dec. 13, 2010 - Val Brickates Kennedy
Wednesday's biggest gaining and declining stocks 4:40 p.m. March 3, 2010 - MarketWatch
Nasdaq hesitates at the 50-day moving average 9:46 a.m. Feb. 18, 2010 - Michael Ashbaugh
S&P 500 settling into the 2004 trading range? 11:38 a.m. Feb. 1, 2010 - Michael Ashbaugh
S&P pulls in from the 1,100 mark 9:15 a.m. Oct. 16, 2009 - Michael Ashbaugh
U.S. benchmarks survive initial test of the 50-day 9:19 a.m. Oct. 5, 2009 - Michael Ashbaugh
Miners, banks weigh on U.K. market 11:07 a.m. Sept. 21, 2009 - Simon Kennedy

Timing And Good Science: Is Now The Time To Get On Board With Nektar? 11:18 a.m. Dec. 3, 2013 - Seeking Alpha
UPDATE: Piper Jaffray Initiates Coverage on Nektar Therapeutics on Expected Attractive Returns 9:53 a.m. Nov. 27, 2013 - benzinga.com
Healthcare coverage initiations roundup 8:55 a.m. Nov. 27, 2013 - Seeking Alpha
FDA to Review Nektar/AZN Drug - Analyst Blog 6:35 p.m. Nov. 20, 2013 - Zacks.com
US Stock Futures Edge Lower Ahead Of Earnings 6:53 a.m. Nov. 19, 2013 - benzinga.com
Nektar, Astra Zeneca Announce NDA for Naloxegol Accepted by FDA 6:07 a.m. Nov. 19, 2013 - benzinga.com
Baxter Advances on Pivotal Study - Analyst Blog 3:10 p.m. Nov. 15, 2013 - Zacks.com
Narrower-than-Expected Q3 Loss at Nektar - Analyst Blog 4:30 p.m. Nov. 8, 2013 - Zacks.com
Nektar Therapeutics' CEO Discusses Q3 2013 Results - Earnings Call Transcript 9:54 p.m. Nov. 7, 2013 - Seeking Alpha
10-Q: NEKTAR THERAPEUTICS 5:10 p.m. Nov. 7, 2013 - Edgar Online - (EDG = 10Q, 10K)
Short Interest In Nektar Therapeutics Falls 12.5% 2:49 p.m. Oct. 11, 2013 - TheStreet.com
Should Investors Have A Sweet Tooth For Nektar? 1:34 p.m. Oct. 11, 2013 - Seeking Alpha
Pipeline Update at Nektar - Analyst Blog 3:45 p.m. Oct. 9, 2013 - Zacks.com
Oversold Conditions For Nektar Therapeutics (NKTR) 12:06 p.m. Oct. 9, 2013 - TheStreet.com
Nektar Therapeutics' CEO Hosts Investor and Analyst R&D Day Conference (Transcript) 6:35 p.m. Oct. 8, 2013 - Seeking Alpha
Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day 10:15 a.m. Oct. 8, 2013 - benzinga.com
Pipeline Progresses at AstraZeneca - Analyst Blog 5:00 p.m. Sept. 30, 2013 - Zacks.com
Trade-Ideas: Nektar Therapeutics (NKTR) Is Today's "Dead Cat Bounce" Stock 10:38 a.m. Sept. 30, 2013 - TheStreet.com
Nektar Reports AstraZeneca Receives EMA Acceptance of Marketing Authorization Application for Naloxegol 4:41 a.m. Sept. 30, 2013 - benzinga.com
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan 8:07 p.m. Sept. 27, 2013 - TheStreet.com

New Research Arrangements, Investor Conference Schedules, Reimbursement Agreements, and NDA Acceptances - Research Report on Quintiles, Insys, HeartWare, Given Imaging, and Nektar 8:00 a.m. Nov. 28, 2013 - PR Newswire
Financing, Special Reports, and Clinical Trial Updates - Research Report on PDL, DexCom, Quintiles, KYTHERA, and Nektar 8:00 a.m. Nov. 20, 2013 - PR Newswire
Morning Research: Inovio Pharma Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 9:03 a.m. Nov. 19, 2013 - PR Newswire
New Drug Application For Naloxegol Accepted By United States Food And Drug Administration 7:00 a.m. Nov. 19, 2013 - PR Newswire
Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A 9:34 a.m. Nov. 13, 2013 - PR Newswire
Baxter Completes Enrollment in Phase III Clinical Trial of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A 9:00 a.m. Nov. 13, 2013 - BusinessWire
Updates on Clinical Studies and Milestone Revenues - Research Report on Cyberonics, West, Nektar, OraSure, and Akorn 8:00 a.m. Nov. 12, 2013 - PR Newswire
Critical Alerts For Salix Pharmaceuticals, Endo Pharmaceuticals, Nektar Therapeutics, Riverbed Technology, and Ubiquiti Networks Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013 4:15 p.m. Nov. 7, 2013 - PR Newswire
Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets 5:00 p.m. Oct. 30, 2013 - PR Newswire
Today's Research: Inovio Pharmaceuticals Inc., Sequenom Inc., Nektar Therapeutics, and Discovery Laboratories Inc. 9:00 a.m. Oct. 28, 2013 - PR Newswire
Nektar and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC) 8:00 a.m. Oct. 24, 2013 - PR Newswire
Dividend Announcements, Earnings Release Scheduled, and Data Presentations from Clinical Studies - Research Report on Questcor, Regeneron, NPS, Incyte, and Nektar 8:00 a.m. Oct. 16, 2013 - PR Newswire
AstraZeneca Announces New Safety Data For Naloxegol In Patients with Opioid-Induced Constipation 10:26 a.m. Oct. 14, 2013 - BusinessWire
Nektar Reports on Advancements with Clinical Pipeline and Introduces New Preclinical Candidates at Investor and Analyst R&D Day 11:15 a.m. Oct. 8, 2013 - PR Newswire
Regulatory Approvals, Public Offerings and Clinical Trial Results - Research Report on Theravance, Synageva, Nektar, Clovis Oncology, and ImmunoGen 8:00 a.m. Oct. 7, 2013 - PR Newswire
Nektar to Host Investor and Analyst R&D Day in New York City 8:30 p.m. Oct. 2, 2013 - PR Newswire
Presentation on Research Findings, Recognitions, Clinical Trial Results, and Orphan Drug Designations - Research Report on Celgene, Biogen Idec, Amgen, Nektar, and Zalicus 8:00 a.m. Oct. 2, 2013 - PR Newswire
Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol 5:30 a.m. Sept. 30, 2013 - PR Newswire
Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee 4:10 p.m. Sept. 26, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...